Acquisition leverage BioDiscovery was acquired by Bionano and integrated into NxClinical, creating a cross-sell opportunity to existing BioDiscovery and Bionano customers for the combined platform, emphasizing the ability to fuse optical genome mapping data with sequencing and microarray data within NxClinical under the leadership of Dr. Soheil Shams.

Clinical interpretation NxClinical introduced ACMG guidelines scoring in a recent release, signaling strong demand for regulatory-grade variant interpretation and reporting in clinical labs.

European footprint With a European headquarters in Cambridge and a US base, there is capability and opportunity to expand sales in Europe and the UK for integrated cytogenetics and molecular genetics analytics.

Enterprise workflows Promote the platform as an enterprise-wide clinical data and reporting system that links research findings to patient care, appealing to mid-sized hospitals and reference labs seeking end-to-end data management.

Ecosystem partnerships Leverage a history of collaborations and recognition in genetic diagnostics to pursue partnerships with diagnostic instrument vendors and labs to embed NxClinical into broader genomics workflows.